← Therapy pipeline
Investigational · Obesity development

Eloralintide

LY3841136 · Eli Lilly

Selective amylin agonist tested as monotherapy and adjunctive treatment.

amylin
Other study areas
Type 2 diabetesSleep apneaKnee osteoarthritis
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorEli Lilly
Targetsamylin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

48-week dose-finding trialMean body-weight reductionBody weight decreased 20% · 48 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed results

Mean body-weight reduction · 48 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
20%
Placebo / comparator
0.4%

Adults with obesity or overweight and a weight-related complication, without diabetes · 9 mg once weekly vs placebo · Trial N=263 · Efficacy estimand; rounded values in published abstract. Results & methods ↗

Nausea and fatigue were common and varied by dose and escalation schedule. Phase 3 confirmation remains important.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1—
GIPGIP—
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3Initiated
Milestone → next

Latest: Phase 3 includes weight management, obstructive sleep apnea, and knee osteoarthritis programs; the published Phase 2 dose-finding study remains evidence context.

Next: Phase 3 ENLIGHTEN weight-management and related-condition outcomes.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies5 records

Phase 3

ENLIGHTEN-1

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight without type 2 diabetes; chronic weight management.

Phase 3

ENLIGHTEN-10

Weight and glycemic control at high cardiovascular risk
Study: Planned / not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

Registered Phase 3 in an estimated 3,000 adults with obesity or overweight, type 2 diabetes and increased cardiovascular risk; weight at week 64 and HbA1c at week 36 are primary endpoints. This is not a cardiovascular-events outcomes trial. Not yet recruiting.

Phase 3

ENLIGHTEN-2

Weight management with type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight and type 2 diabetes; weight-management outcomes.

Phase 3

ENLIGHTEN-4

Weight management with knee osteoarthritis
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight and painful knee osteoarthritis; assesses weight and osteoarthritis outcomes.

Phase 3

ENLIGHTEN-6

Add-on weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with persistent obesity or overweight despite stable weekly incretin-based therapy; includes participants with or without type 2 diabetes.

Phase 2 studies1 record

Related conditions and outcomes

Phase 3 studies1 record

Phase 3

ENLIGHTEN-3

Sleep-apnea outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity and moderate-to-severe obstructive sleep apnea; master protocol includes separate PAP-use substudies.